Related Experiment Video
Updated: Jan 9, 2026
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
Use and Persistence of Beta 3-Adrenoceptor Agonists for the Treatment of Overactive Bladder
Naoki Wada1, Kotona Miyauchi1, Taichiro Ishimaru1
1Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan.
Introduction:
This study aimed to investigate the real-world usage patterns and persistence rates of mirabegron and vibegron in the treatment of overactive bladder (OAB).
Methods:
A retrospective review was conducted on patients who received either mirabegron or vibegron as their initial treatment for OAB between August 2022 and December 2024. Two types of persistence rates were assessed: (1) the individual persistence for each drug (persistence rate I) and (2) the overall β3-adrenergic agonist persistence among patients who switched between mirabegron and vibegron (persistence rate II).
Results:
In total, 192 patients were included, with 128 (66.7%) receiving mirabegron and 64 (33.3%) receiving vibegron. Mirabegron was more commonly prescribed to male patients. The median persistence rate I was 11 months for mirabegron (95% CI, 6-16) and was not reached for vibegron (95% CI, 9 months to not estimable) (p = 0.071). Among those who discontinued treatment, 40.7% of mirabegron users and 17.6% of vibegron users switched to the alternative β3 agonist. The median persistence rate II was 16 months for mirabegron (95% CI, 8-20) and not reached for vibegron (95% CI, 9 months to not estimable) (p = 0.352).
Conclusion:
The higher discontinuation rate of mirabegron may reflect the availability of vibegron as an alternative treatment option. The complementary use of both β3 agonists could play a key role in optimizing OAB management.
Related Concept Videos
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:18Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:26Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers